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Abstract
the cost of treatments especially in conditions where
multiresistant bacteria are involved are a major issue in
times where in most developed countries in the world
payment  systems  based  on  diagnoses-related-groups
(DRg) are in place. there is great evidence that espe-
cially the length of stay in hospital (loS), the time in
the  intensive  care  unit  (Icu-days)  and  the  hours  of
mechanical ventilation (HMv) are major cost drivers.
while established methods of pharmacoeconomical
analyses focus on the efficiency of drugs from health-
care system perspective, these data are often not suffi-
cient for improving treatment strategies in a given hos-
pital context.
we developed a system that allows the analysis of
patients with severe infections on the basis of routine
data that is also used for reimbursement. these data
contain  a  lot  of  information  concerning  the  clinical
conditions. by using the IcD-coding we developed an
algorithm which allows the detection of patients with
infections and gives information on the potential fi-
nancial outcome of these patients. by using the analy-
sis it is possible to identify subsets of infections and
the  patient  records  that  had  a  potentially  negative
DRg-result,  i.e.  the  costs  are  higher  than  the  reim-
bursement. when identified the patient records under-
go a peer review, where the clinical situation and the
antibiotic therapy are reviewed by medical experts. In
case simulations it is possible to find out if a different
therapeutic approach, e.g. by different choices in initial
(empirical)  antibiotic  treatment  would  have  caused
other outcomes.
Data driven analyses together with peer reviews of
patient records are a useful tool to examine antibiotic
treatment strategies and to establish changes that again
can be reviewed on a regular basis. Doing this a conti-
nous improvement process can be established in hos-
pitals which can lead to a better balance of clinical and
economical  outcomes  in  patients  with  severe  infec-
tions. Moreover these analyses are helpful in assessing
the literature on economical benefits of new therapies.
Abbreviations: 
aloS = average length of stay in a given DRg, basis
for determining whether a patient causes more costs
than reimbursement; 
caP = community acquired pneumonia; 
cc  =  complications  and  comorbidities,  conditions
(like secondary diagnoses) that cause higher resource
consumption; 
DRg = diagnoses related groups, systems to classify
patients based on their resource consumptions; 
HaP = hospital acquired pneumonia; 
HMv = hours of mechanical ventilation; 
Icu-days = treatment days on an intensive care unit;
loS = length of stay in hospital; 
MDS = medical services of the statuary health insur-
ance in germany; 
Qaly = quality adjusted life years; 
w = with; 
w/o = without
IntRoDuctIon
antibiotic therapy directed against multiresistent bac-
teria  is  a  significant  cost  driver  in  clinical  medicine.
Due to various reasons, the costs of new antibiotics
are comparatively high and some multiresistant bacte-
ria can or should only be treated with new antibiotics.
Moreover,  most  complicated  bacterial  infections  re-
quiring long treatment durations occur in the hospital
setting, often in intensive care units. It is a well estab-
lished notion that prolonged length of stay in the hos-
pital (loS), the time spent in intensive care units (Icu
days) and the hours of mechanical ventilation (HMv)
are the main cost drivers in this setting [1-6].
the evaluation of the economical effectiveness of
pharmacological therapies is gaining more and more
importance. while most of these pharmacoeconomi-
cal analyses are intended to show effectiveness of a
new drug versus the current standard-of-care from a
healthcare system perspective (cost-effectiveness stud-
ies, prospective modelling, using quality-adjusted-life-
years (Qualys) and other parameters), these studies
do not necessarily answer the budget-related questions
of clinicians or even the administrators in a hospital
[7-10]. 
finally, in most developed countries so-called diag-
nosis-related groups (DRg) are used for hospital bud-
geting, reimbursement or resource allocation. DRgs
are payment groups that determine the reimbursement
for a certain type of patient group that was found to
be economically homogenous.  for example, the ger-
many system provides DRg-directed payment for res-
piratory  tract  infections  with  or  without  „complica-
tions  or  comorbidities  (cc)“.  the  following  table
gives an overview of DRgs for respiratory tract infec-
tions,  their  cost-weights,  their  payment  (assuming  a
base price for cost weight 1.0 of ᾬ 2,900.-) and the re-
lated length of stay (loS) in hospital, see table 1.
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bursement  or  budget  allocation  in  most  developed
countries in the world. nearly every country in Eu-
rope has DRg-systems in use [15].
without drilling too deep into the complicated ger-
man  DRg  System  and  translating  all  the  DRg-de-
nominators, we point out, that DRg payments for one
particular set of conditions – like respiratory tract in-
fections  –  vary  according  to  various  cost-modifiers.
one  of  these  factors  is  the  occurence  of  multire-
sistent bacteria (see bold letters in the table).
However, the payment for a given DRg is fixed at a
certain amount. the german costing study includes
annually calculated average costs in a matrix of cost
types  (such  as  staff,  pharmaceuticals,  etc.)  and  cost
centers (such as normal ward, oR, Icu, etc.). this re-
sults in a costing matrix with up to 100 so-called cost
modules.  Moreover  a  national  loS  “benchmark“  is
available, and these data  are published in the internet
(for each DRg). after the introduction of DRgs, op-
timizing the loS has turned out as an important lever
to achieve higher profitability [11]. yet, this notion has
not yet been fully acknowledged by everyone in the
medical community [12].
as an example, table 2 shows the cost matrix of
E77B – Respiratory infections with complex diagnosis
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Table 1. overview of DRg E77 – respiratory tract infections.
Table 2. cost matrix for DRg E77b.
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dren, with treatment of  multiresistent bacteria, hospital
stay longer than 72 hrs
based on the known „limits“ that must be observed
to avoid losing money in DRg-reimbursed treatments,
analyses can be done on an individual hospitalﾴs data
to determine whether the current treatment strategies
in a hospital lead to a sustainable balance of cost and
medical need [13, 14]. 
coming  from  this  idea,  the  development  of  a
DRg-based approach to the analysis of infections and
the prove-of-concept were the major questions to be
dealt with in this publication.
MatERIalS anD MEtHoDS
as  in  DRg-based  payment  systems,  the  coding 
of diagnoses as primary (the reason why the patient
got  admission  to  the  hospital)  and  secondary 
(relevant  complications  and  comorbidities  that 
caused  resource  consumption)  diagnoses  is  the 
cornerstone of finding the correct DRg, we assumed
that  the  coding  quality  in  terms  of  completeness 
and accuracy pretty well reflects the clinically relevant
situation, especially in case of infections. we devel-
oped  an  algorithm  that  contains  over  100  IcD-
codes  representing  infections  and/or  bacterial
pathogens.  Hospital-acquired  versus  community-
acquired infections were assumed to be represented
by the assignment as „primary“ (or main) diagnosis 
or „secondary“ diagnosis. Moreover, we tried to rule
out  coding  errors  such  as  the  implausible  use  of 
the  same  IcD  code  as  primary  and  secondary 
diagnosis.  Hospital  acquired  pneumonias  (HaP) 
may  be  indicated  by  a  special  IcD-code  (u69.00!)
used  to  distinguish  between  community  acquired
pneumonia  (caP)  and  HaP  in  the  german 
system.
using the minimal basic dataset (MbDS) of a coun-
try – in germany it is defined by ﾧ21 of the hospital
financing act and thus called ﾧ21-data – for one hospi-
tal or a set of hospitals, it is possible to „decode“ in-
fections from the DRg data.
table 3 displays the basic data model used to re-
trieve  information  on  infections  and  bacterial
pathogens from coded IcD-10 data.
as in some cases, bacterial pathogens are part of
the  IcD-code  of  the  infections,  counting  infections
and the bacteria involved respect this fact by listing
some IcD-codes as infections and as bacteria. 
See table 4 for an example. 
using this methodology, we were able to decode in-
fections from routine DRg data. after implementa-
tion  of  these  data  in  a  business  information  ware-
house (bI) software, it is now possible to answer the
following questions:
- which infections caused by which bacteria occur in
the hospitals?
- which  loS  is  associated  to  which  infection  and
does it imply a risk of losing reimbursement for the
hospital?
- which DRgs are the ones most likely impacted by
infections?
once identified, the DRgs with a high number of
infections or those patients that cause the highest loss
in DRg-reimbursement due to infections may be fur-
ther analyzed.
In peer reviews, the antibiotic therapy strategy for
each case may be compared against the expected cost
average in the respective DRg, the actual cost and the
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Table 3. Entity relationship model of the „decoding infections“ database.
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therapeutic strategy.
RESultS
Differences in length of stay that cause inefficiency can
be detected and assigned to various types of infections.
table  5  shows  an  overview  of  certain  infections
and the loS of patients having these infections com-
pared  to  the  loS  of  patients  being  in  the  hospital
without an infection.
If the loS is higher with an infection, this does
not necessarily imply that there is an economic loss
for the hospital, as expensive cases usually also entail
more revenue. by knowing that loS is the key cost
driver  in  a  DRg-based  system,  an  analysis  can  be 
performed  how  many  patients  meet  the  average 
loS  (aloS)  of  the  DRg  –  as  defined  by  the 
national  benchmark  –  and  how  many  patients  stay
longer.  those  patients  staying  longer  are  the 
patients  that  cost  more  than  the  hospital  is  reim-
bursed for.
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Table 5. loS with and without infections.
without infections:
7,3 days (green block
line)
with hospital acquired
pneumonia (HaP) 21-28
days (pink line) 
Table 4. association of bacterial pathogens and IcD-codes..
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curve, cumulative = brown curve) for 1) all patients in
a hospital and 2) patients having a postoperative infec-
tion  such  as  wound  infections,  peritonitis  or  other
oR–related infections:
using individual patient cases for analysis, the indi-
vidual  DRg  may  be  used  and  the  actual  antibiotic
therapy strategy may be compared versus an optimum
setting. Quite often it is possible to show that a state-
of-the art therapy causes less cost.
table 8 shows a case simulation for a given DRg –
result (a13E – mechanical ventilation 95-250 hrs). by
examining the medical record, the reviewers found that
by optimizing antibiotic therapy (i.e. starting the eventu-
ally effective therapy with tigecycline 3 days earlier) the
Icu-stay and the loS could have been 2 days shorter.
Moreover, by starting the adequate therapy earlier, three
days of ineffective and expensive therapy (in this case
meropenem plus ciprofloxacin) could have been avoid-
ed. In the end, the hospital would have had small gain
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Table 6. loS for all patients of a hospital – good result: 76% of all patients can be discharged before reaching the aloS (mvD
in the figure).
Table 7. loS distribution for patients with postoperative infections. although the national aloS of these DRgs  is 21.9 days
(indicating that the DRg-reimbursement is higher than the hospital average) only 50% of these patients can be discharged be-
fore aloS. that means half of the patients cost presumably more than the hospital is being reimbursed for.
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tion. comparing national standard cost (section “InEK-
Daten” in the picture) with actual cost (section “Ist-Sit-
uation”) shows that the hospital spends more than it is
reimbursed (-1,881.23 ᾬ). by simulating the case with the
optimized therapy option (section “variante” in the pic-
ture) the economic result shows a surplus of 1,223.10ᾬ.
the findings of other studies and the results from
the data easily can be reproduced also in the results of
individual case reviews. the main cost drivers are:
- length of stay in hospital → Possible reason: De-
layed start of effective antibiotic therapy
- complications related to antibiotic therapy → most
frequent: renal failure
- use of inadequate antibiotics that turn out to be in-
effective
- longer Icu stay 
- Prolonged duration of mechanical ventilations
DIScuSSIon
Decoding infections from DRg routine data is fea-
sible, comparatively easy and can be done with little
effort of time and expenses as the data are easily avail-
able for each hospital. validations in several hospitals
were done by using the results and reviewing selected
medical records to verify whether the „decoded“ in-
fection was actually mentioned in the record. very lit-
tle variances were found to be due to coding varia-
tions. while germany has coding standards for diag-
noses and procedures, errors may still occur. the actu-
al accuracy of the coding is very good. according to
the medical services of the statuary health insurance
in germany (MDS) 11% of all hospital DRg reim-
bursements are claimed to be wrong and in 40% of
the claims actual errors are found. that means that
nearly 96% of the coding is correct, as no claim is is-
sued or no error is found [15].
It is clearly possible to identify cases that are more
expensive  than  the  DRg  system  recommends.  In
many  of  these  cases,  sound  medical  reasons  caused
the extended loS, but there is a substantial part of
the reviewed cases that suggest opportunities to opti-
mize the antibiotic therapy strategy. 
concluSIonS
analysis on the basis of DRg routine data is an easy
way to “decode” infections in a hospital setting and di-
rectly connect them to economic results.
Establishing a peer review of the medical records
of cases producing financial loss may identify oppor-
tunities to optimize treatment strategies.
loS,  number  of  complications,  Icu-days  and
hours of mechanical ventilation are good endpoints to
be used in the assessment of the economical effects of
individual antibiotics.
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Table 8. DRg and individual case-based simulation of optimized antibiotic therapy strategies.
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